UNKNOWN · LOW discovery confidence
Camrelizumab
Reported program or trial event; neither availability nor investment recommendation
Why this survived
Selected for further evidence review: supply failure. Discovery is not buyer qualification.
MODEL INFERENCE · Source 1UNKNOWN
Next Best Diligence Question
What primary evidence resolves human efficacy for Camrelizumab in this exact treatment and indication context?
Why it matters and what could change
Human Signal: human efficacy is UNKNOWN; resolve this component before making a stronger decision.
Evidence needed: Source-bound, dated evidence for human efficacy, including contradictory findings and scope limitations.
Likely source: Official trial arm-level results, primary PubMed human studies and protocols
Continue diligence, deprioritize or retain UNKNOWN; no automatic promotion.
Fatal flaw: Unknown. No known fatal flaw is not asserted without complete scoped review.
Evidence completeness — coverage, not confidence
Human Signal: 0 / 5 gate components adjudicated
Cheap Truth: 0 / 6 gate components adjudicated
Clean Rights: 0 / 6 gate components adjudicated
Market Pull: 0 / 5 gate components adjudicated